In the latest 2023 ESCGuideline for the Management of Heart Failure [50], SGLT-2 inhibitors(dapagliflozin or empagliflozin) are recommended to diminish the risk ofhospitalization or cardiovascular death (Class I, Level A) for patients with HFwith mildly reduced ejection fraction (HFmrEF). Here, SLC5A2 is linked to heart failure.